DiaMedica Therapeutics Advances DM199 Preeclampsia Clinical Program Following FDA Meeting

Reuters12-18 21:45

DiaMedica <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Advances DM199 Preeclampsia Clinical Program Following FDA Meeting

DiaMedica Therapeutics Inc. has announced the completion of a pre-Investigational New Drug $(IND)$ meeting with the U.S. Food and Drug Administration (FDA) regarding a planned study of DM199 for preeclampsia. The FDA requested an additional non-clinical, 10-day modified embryo-fetal development and pre- and postnatal development study in a rabbit model, with results expected by the second quarter of 2026. Additionally, an ongoing Phase 2 investigator-sponsored trial of DM199 in South Africa has dosed over 30 women with late-stage preeclampsia. Interim data from this trial have shown statistically significant reductions in blood pressure and dilation of intrauterine arteries, with no placental transfer of DM199 observed. The full results of the rabbit study are anticipated in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251218113728) on December 18, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592041909?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 21:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592041909","market":"nz","top_or_hot":-1,"title":"DiaMedica Therapeutics Advances DM199 Preeclampsia Clinical Program Following FDA Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      DiaMedica <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Advances DM199 Preeclampsia Clinical Program Following FDA Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DMAC\">DiaMedica Therapeutics Inc.</a> has announced the completion of a pre-Investigational New Drug <a href=\"https://laohu8.com/S/IND\">$(IND)$</a> meeting with the U.S. Food and Drug Administration (FDA) regarding a planned study of DM199 for preeclampsia. The FDA requested an additional non-clinical, 10-day modified embryo-fetal development and pre- and postnatal development study in a rabbit model, with results expected by the second quarter of 2026. Additionally, an ongoing Phase 2 investigator-sponsored trial of DM199 in South Africa has dosed over 30 women with late-stage preeclampsia. Interim data from this trial have shown statistically significant reductions in blood pressure and dilation of intrauterine arteries, with no placental transfer of DM199 observed. The full results of the rabbit study are anticipated in the future.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251218113728) on December 18, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DiaMedica Therapeutics Advances DM199 Preeclampsia Clinical Program Following FDA Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDiaMedica Therapeutics Advances DM199 Preeclampsia Clinical Program Following FDA Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-18 21:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      DiaMedica <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Advances DM199 Preeclampsia Clinical Program Following FDA Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DMAC\">DiaMedica Therapeutics Inc.</a> has announced the completion of a pre-Investigational New Drug <a href=\"https://laohu8.com/S/IND\">$(IND)$</a> meeting with the U.S. Food and Drug Administration (FDA) regarding a planned study of DM199 for preeclampsia. The FDA requested an additional non-clinical, 10-day modified embryo-fetal development and pre- and postnatal development study in a rabbit model, with results expected by the second quarter of 2026. Additionally, an ongoing Phase 2 investigator-sponsored trial of DM199 in South Africa has dosed over 30 women with late-stage preeclampsia. Interim data from this trial have shown statistically significant reductions in blood pressure and dilation of intrauterine arteries, with no placental transfer of DM199 observed. The full results of the rabbit study are anticipated in the future.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251218113728) on December 18, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL7KmDGP:1","article_id":"2592041909","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592041909","pubTimestamp":1766065522,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"DiaMedica Therapeutics Inc. has announced the completion of a pre-Investigational New Drug  meeting with the U.S. Food and Drug Administration  regarding a planned study of DM199 for preeclampsia. The FDA requested an additional non-clinical, 10-day modified embryo-fetal development and pre- and postnatal development study in a rabbit model, with results expected by the second quarter of 2026. Additionally, an ongoing Phase 2 investigator-sponsored trial of DM199 in South Africa has dosed over 30 women with late-stage preeclampsia. Interim data from this trial have shown statistically significant reductions in blood pressure and dilation of intrauterine arteries, with no placental transfer of DM199 observed. The full results of the rabbit study are anticipated in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","DMAC":"DiaMedica Therapeutics Inc."},"translate_title":"DiaMedica Therapeutics在FDA会议后推进DM199先兆子痫临床项目","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DMAC":0.9},"content_text":"DiaMedica Therapeutics Advances DM199 Preeclampsia Clinical Program Following FDA Meeting\n    \n\nDiaMedica Therapeutics Inc. has announced the completion of a pre-Investigational New Drug $(IND)$ meeting with the U.S. Food and Drug Administration (FDA) regarding a planned study of DM199 for preeclampsia. The FDA requested an additional non-clinical, 10-day modified embryo-fetal development and pre- and postnatal development study in a rabbit model, with results expected by the second quarter of 2026. Additionally, an ongoing Phase 2 investigator-sponsored trial of DM199 in South Africa has dosed over 30 women with late-stage preeclampsia. Interim data from this trial have shown statistically significant reductions in blood pressure and dilation of intrauterine arteries, with no placental transfer of DM199 observed. The full results of the rabbit study are anticipated in the future.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251218113728) on December 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592041909","isCrawlerRequest":true}